Loading
Inati-cel is a Chinese CAR-T for adults with acute lymphoblastic leukaemia that has come back or stopped responding, approved in 2023.
Developed by Juventas Cell Therapy with the Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences, and approved by the NMPA in 2023 for adult relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia, the first CAR-T approved in China for leukaemia. It illustrates how China's academic haematology centres have become the origin of approved cell therapies rather than only trial sites.
Autologous CD19-directed CAR-T cells using a novel CD19 binder (HI19a) developed at the Institute of Hematology, Chinese Academy of Medical Sciences, in Tianjin. Connects to CD19.
1.Inaticabtagene autoleucel slips into a pocket on CD19.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2023 | Adult relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Inaticabtagene autoleucel" OR ABSTRACT:"Inaticabtagene autoleucel" OR TITLE:"Yuanruida" OR ABSTRACT:"Yuanruida" OR TITLE:"inati-cel" OR ABSTRACT:"inati-cel" OR TITLE:"CNCT19" OR ABSTRACT:"CNCT19") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Inaticabtagene autoleucel, not a curated reading list.
Shares CAR-T cell therapy, Acute lymphoblastic leukaemia and the tag china.
Shares CD19, CAR-T cell therapy and the tag china.
Shares CD19, CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares Acute lymphoblastic leukaemia and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.